At the time of writing, Ironwood Pharmaceuticals Inc [IRWD] stock is trading at $0.89, up 1.12%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IRWD shares have gain 22.27% over the last week, with a monthly amount drifted -39.14%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ironwood Pharmaceuticals Inc [NASDAQ: IRWD] stock has seen the most recent analyst activity on April 15, 2025, when Wells Fargo downgraded its rating to a Equal Weight. Previously, Jefferies downgraded its rating to Hold on April 15, 2025. On April 14, 2025, downgrade downgraded it’s rating to Mkt Perform. Leerink Partners started tracking the stock assigning a Market Perform rating and suggested a price target of $5 on September 09, 2024. CapitalOne downgraded its rating to a Equal Weight and reduced its price target to $4 on August 08, 2024. Craig Hallum started tracking with a Buy rating for this stock on January 17, 2024, and assigned it a price target of $21. In a note dated December 14, 2023, Wells Fargo initiated an Overweight rating and provided a target price of $20 on this stock.
For the past year, the stock price of Ironwood Pharmaceuticals Inc fluctuated between $0.59 and $8.45. Currently, Wall Street analysts expect the stock to reach $4 within the next 12 months. Ironwood Pharmaceuticals Inc [NASDAQ: IRWD] shares were valued at $0.89 at the most recent close of the market. An investor can expect a potential return of 349.44% based on the average IRWD price forecast.
Analyzing the IRWD fundamentals
According to Ironwood Pharmaceuticals Inc [NASDAQ:IRWD], the company’s sales were 351.41M for trailing twelve months, which represents an -22.98% plunge. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.28%, Pretax Profit Margin comes in at 0.19%, and Net Profit Margin reading is 0.08%. To continue investigating profitability, this company’s Return on Assets is posted at 0.08, Equity is -0.09 and Total Capital is 0.31. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.99.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.8278 points at the first support level, and at 0.7670 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.9415, and for the 2nd resistance point, it is at 0.9944.
Ratios To Look Out For
It is important to note that Ironwood Pharmaceuticals Inc [NASDAQ:IRWD] has a current ratio of 4.69. Further, the Quick Ratio stands at 4.69, while the Cash Ratio is 2.28. Considering the valuation of this stock, the price to sales ratio is 0.41 and price to earnings (TTM) ratio is 82.27.
Transactions by insiders
Recent insider trading involved MCCOURT Thomas A, Chief Executive Officer, that happened on Feb 10 ’25 when 0.14 million shares were sold. Principal Accounting Officer, Silver Ronald completed a deal on Feb 10 ’25 to sell 12048.0 shares. Meanwhile, SVP, CMO, Head-Res&Drug Shetzline Michael sold 41269.0 shares on Feb 10 ’25.
